

Dariusz T Aladowski

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3570256/publications.pdf>

Version: 2024-02-01

28
papers

1,350
citations

567281

15
h-index

580821

25
g-index

29
all docs

29
docs citations

29
times ranked

1436
citing authors

#	ARTICLE	IF	CITATIONS
1	An improved MIT assay. <i>Journal of Immunological Methods</i> , 1993, 157, 203-207.	1.4	352
2	The International EU/COLIPA In Vitro Phototoxicity Validation Study: Results of Phase II (Blind Trial). Part 1: The 3T3 NRU Phototoxicity Test. <i>Toxicology in Vitro</i> , 1998, 12, 305-327.	2.4	251
3	Practical Aspects of the Validation of Toxicity Test Procedures. <i>ATLA Alternatives To Laboratory Animals</i> , 1995, 23, 129-146.	1.0	240
4	<i>In Vitro</i> Phototoxicity Testing. <i>ATLA Alternatives To Laboratory Animals</i> , 1994, 22, 314-348.	1.0	86
5	Allotransplantation of Cultured Parathyroid Progenitor Cells Without Immunosuppression: Clinical Results. <i>Transplantation</i> , 2007, 83, 734-740.	1.0	51
6	The possible role of factor H in colon cancer resistance to complement attack. <i>International Journal of Cancer</i> , 2008, 122, 2030-2037.	5.1	44
7	Clinical Development and Commercialization of Advanced Therapy Medicinal Products in the European Union: How Are the Product Pipeline and Regulatory Framework Evolving?. <i>Human Gene Therapy Clinical Development</i> , 2017, 28, 126-135.	3.1	44
8	Dominant <i>ELOVL1</i> mutation causes neurological disorder with ichthyotic keratoderma, spasticity, hypomyelination and dysmorphic features. <i>Journal of Medical Genetics</i> , 2018, 55, 408-414.	3.2	41
9	Manufacturing, characterization and control of cell-based medicinal products: challenging paradigms toward commercial use. <i>Regenerative Medicine</i> , 2015, 10, 65-78.	1.7	40
10	Preserved tissue allografts in reconstructive surgery. <i>Cell and Tissue Banking</i> , 2001, 2, 103-112.	1.1	33
11	The Establishment of Human Research Tissue Banking in the UK and Several Western European Countries. <i>ATLA Alternatives To Laboratory Animals</i> , 2001, 29, 125-134.	1.0	28
12	The Availability of Human Tissue for Biomedical Research: The Report and Recommendations of the ECVAM Workshop 32. <i>ATLA Alternatives To Laboratory Animals</i> , 1998, 26, 763-77.	1.0	27
13	Reconstruction method for extended depth-of-field optical diffraction tomography. <i>Methods</i> , 2018, 136, 40-49.	3.8	21
14	Cell and Gene Therapies: European View on Challenges in Translation and How to Address Them. <i>Frontiers in Medicine</i> , 2018, 5, 158.	2.6	17
15	In vitro reconstruction of full thickness human skin on a composite collagen material. <i>Cell and Tissue Banking</i> , 2001, 2, 165-171.	1.1	15
16	Fluvastatin increases tyrosinase synthesis induced by α -melanocyte-stimulating hormone in B16F10 melanoma cells. <i>Pharmacological Reports</i> , 2010, 62, 164-169.	3.3	12
17	Synthesis and anticancer activity of 7-hydroxycoumarinyl gallates. <i>Pharmacological Reports</i> , 2015, 67, 236-244.	3.3	11
18	Mosaic <i>IL6ST</i> variant inducing constitutive GP130 cytokine receptor signaling as a cause of neonatal onset immunodeficiency with autoinflammation and dysmorphism. <i>Human Molecular Genetics</i> , 2021, 30, 226-233.	2.9	8

#	ARTICLE	IF	CITATIONS
19	Culture of the primary corneal epithelium as a potential component of test batteries for eye irritancy testing. <i>Toxicology in Vitro</i> , 2005, 19, 875-878.	2.4	7
20	Barriers to Validation. <i>ATLA Alternatives To Laboratory Animals</i> , 2008, 36, 459-464.	1.0	7
21	Variable degree of mosaicism for tetrasomy 18p in phenotypically discordant monozygotic twins – Diagnostic implications. <i>Molecular Genetics & Genomic Medicine</i> , 2021, 9, e1526.	1.2	7
22	ESTIV questionnaire on the acquisition and use of primary human cells and tissue in toxicology. <i>Toxicology in Vitro</i> , 2005, 19, 1009-1013.	2.4	3
23	Experimental immunology Xenotransplantation of human cultured parathyroid progenitor cells into mouse peritoneum does not induce rejection reaction. <i>Central-European Journal of Immunology</i> , 2014, 3, 279-284.	1.2	3
24	An Evaluation of Sterilisation Processes. <i>ATLA Alternatives To Laboratory Animals</i> , 2008, 36, 585-590.	1.0	1
25	ECVAM'S Activities in the EU Candidate Countries. <i>ATLA Alternatives To Laboratory Animals</i> , 2002, 30, 203-205.	1.0	0
26	The expression of membranous complement inhibitors CD46, CD55 and CD59 in the primary and metastatic colon cancer cell lines derived from the same patient. <i>Central-European Journal of Immunology</i> , 2013, 4, 549-555.	1.2	0
27	Comparison of the expression of complement regulatory proteins CD46, CD55 and CD59 in primary colon cancer and synchronous/metachronous liver metastases. <i>Central-European Journal of Immunology</i> , 2013, 4, 543-548.	1.2	0
28	The Three Rs and Alternatives in the Visegrád (V4) Countries. , 2019, , 59-70.		0